NetworkNewsBreaks – Energy Fuels Inc. (NYSE Amer
Post# of 388
Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium producer in the United States, is partnering with RadTran LLC to evaluate the recovery of thorium, and potentially radium, from UUUU’s existing rare earth carbonate and uranium process streams for use in producing medical isotopes for emerging targeted alpha therapy (“TAT”) cancer therapeutics. The partnership is outlined in a strategic alliance agreement and has the potential to develop commercial technologies and sources of isotopes needed for a new domestic medical supply chain. RadTran is a Colorado-based tech-development company working on closing critical gaps in the procurement of medical isotopes for various applications. “At its heart, the Energy Fuels’ Alliance with RadTran is about maximizing the value and human benefit of our existing uranium and rare earth feeds at the White Mesa Mill,” said Energy Fuels president and CEO Mark S. Chalmers in the press release. “Energy Fuels has a long track record of ethically and responsibly processing a wide variety of naturally occurring radioactive materials at the White Mesa Mill for the recovery of uranium and, more recently, rare earths. In our view, recovering medical isotopes from these same streams that would otherwise be lost to direct disposal is a great way to maximally use all of our feeds. Indeed, we are essentially replicating China’s monazite plan. China purchases monazite from around the globe, recovers the uranium for use in their nuclear industry, recovers the thorium presumably for use in their nuclear and pharmaceutical industries, and recovers the rare earths for processing into advanced materials needed for various clean energy and advanced technologies. Our White Mesa Mill is a facility unique to the United States that has the potential to do the same thing at world standards. . . . We believe Energy Fuels has the potential to create a domestic supply of thorium and possibly radium that can be harvested using RadTran’s technologies for use in the production of the next generation of cancer therapies, a potentially multibillion dollar industry.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer